Cobalt™ XT ICDs and CRT-Ds with BlueSync™ technology enable tablet-based programming and app-based remote monitoring. These devices include an automated antitachycardia pacing (ATP) algorithm and are compatible with a simplified heart failure risk stratification tool.Download Brochure
Meet Cobalt XT ICDs and CRT-Ds
Exclusive ATP algorithm, heart failure risk stratification, tablet-based programming and app-based remote monitoring, extended longevity, and 40 J on all shocks.
Mean longevity projections based on CareLink™ patient data*
Option for 40 J energy delivery on all shocks, including the first
Intrinsic ATP™ is the only automated and smart ventricular antitachycardia pacing (ATP) algorithm that provides individualized therapy in real time.
In a virtual modeling study, Intrinsic ATP’s termination rate was 17 percentage points higher than traditional ATP (burst) with no difference in acceleration rate.7
ATP designed for each VT
If VT is redetected, iATP automatically adjusts the next ATP sequence.
Discover Cobalt XT's full suite of algorithms to help detect, reduce, and respond to atrial fibrillation (AF).
Cobalt XT ICDs and CRT-Ds with BlueSync technology enable secure, wireless communication.
Tablet-based CareLink SmartSync™ device manager
Cobalt XT ICDs and CRT-Ds
MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator
CareLink network and the
Get Connected service
TriageHF™¶ is a simplified, integrated heart failure risk assessment tool that alerts clinicians to clinically relevant changes in a patient’s status that may lead to a heart failure decompensation.
clinics# can leverage
the technology for
all ICD & CRT
Discover exclusive features and algorithms available in Cobalt XT ICDs and CRT-Ds.
These values should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.
With AdaptivCRT™ programmed to BiV and LV.
Energy delivered at connector block into a 50 Ω ± 1% load.
Energy stored at charge end on capacitor.
From ADVANCE III, using ATP during charging along with NID = 30/40 programming, ATP reduced shocked episodes by 52%.8
TriageHF is not an alarm. The TriageHF assessment does not replace heart failure assessments in standard clinical practice. Medical treatment should not be modified remotely based solely on the TriageHF assessment. Interpretation of the TriageHF assessment requires clinical judgement by a medical professional. The TriageHF assessment should be used in conjunction with professional guidelines for patient management decisions.
TriageHF requires clinic activation. Contact your local Medtronic sales representative for activation requirements
Medtronic Claria MRI™ Quad CRT-D SureScan™ & Amplia MRI™ Quad CRT-D SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201802366 EN.
Medtronic Cobalt™ XT HF Quad MRI SureScan™ Model DTPA2QQ device manual.
Medtronic Evera MRI™ XT DR SureScan™ and Evera MRI™ S DR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201802366 EN.
Medtronic Cobalt™ XT DR ICD MRI SureScan™ Model DDPA2D4 device manual.
Medtronic Visia AF™ VR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201802366 EN.
Medtronic Cobalt™ XT VR ICD MRI SureScan™ Model DVPA2D4 device manual.
Swenson DJ, Taepke RT, Blauer JJE, et al. Direct comparison of a novel antitachycardia pacing algorithm against present methods using virtual patient modeling. Heart Rhythm. September 2020;17(9):1602-1608.
Arenal A, Proclemer A, Kloppe A, et al. Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial. Europace. November 2016;18(11):1719-1725.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.